Questioning Authority: French Court Overturns Health Agency's Diabetes Guidelines, Citing Conflict Of Interest Rules
This article was originally published in The Pink Sheet Daily
Executive Summary
The French court's action may force the country's regulatory bodies to take a closer look at their links with the pharmaceutical industry and reflects further fall-out from the Mediator scandal.
You may also be interested in...
Mediator Is Tip Of EU Parliament's Probe Into EMA; Funding Held In Balance
The European Parliament blocks approval of EMA's budget accounts, citing handling of Mediator and broader conflict of interest concerns.
Mediator Is Tip Of EU Parliament's Probe Into EMA; Funding Held In Balance
The European Parliament blocks approval of EMA's budget accounts, citing handling of Mediator and broader conflict of interest concerns.
Boehringer/Lilly's Linagliptin Approved: Can Renal Flexibility Unlock The DPP-4 Market?
Tradjenta's label supporting use in renally-impaired patients, with no need to adjust dose, could help differentiate the product's safety profile in a competitive space.